Cosmo Pharmaceuticals (OTCMKTS:CMOPF – Get Free Report) was the recipient of a significant increase in short interest in September. As of September 15th, there was short interest totaling 15,837 shares, an increase of 112.6% from the August 31st total of 7,450 shares. Based on an average trading volume of 885 shares, the days-to-cover ratio is presently 17.9 days.
Cosmo Pharmaceuticals Stock Performance
CMOPF stock opened at C$65.00 on Tuesday. Cosmo Pharmaceuticals has a fifty-two week low of C$63.49 and a fifty-two week high of C$169.90. The business has a 50 day moving average price of C$72.22 and a 200 day moving average price of C$89.09.
Cosmo Pharmaceuticals Company Profile
Cosmo Pharmaceuticals N.V. is a specialty pharmaceutical company focused on developing, manufacturing and commercializing products for gastrointestinal and dermatological conditions. Founded in 1997, the company is headquartered in Dublin, Ireland, and has research, development and manufacturing operations in Europe.
Cosmo’s gastrointestinal portfolio includes therapies based on mesalamine and budesonide, including products marketed under the Lialda, Mezavant and Uceris brands through commercial partners in various markets.
See Also
- Five stocks we like better than Cosmo Pharmaceuticals
- Apple, Meta, and SpaceX Are Driving a Device Boom—These 3 Stocks Could Benefit
- 2 Short-Squeeze Candidates Waiting for the Right Catalyst
- MongoDB Stock Drops 17% After CEO Exit—What Investors Should Know
- Bernstein Downgrades 3 Cybersecurity Stocks: How Concerned Should Investors Be?
Receive News & Ratings for Cosmo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cosmo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
